- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | ArriVent Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Mo | ArriVent BioPharma, Inc.: ArriVent Appoints Kristine Peterson to its Board of Directors | 1 | GlobeNewswire (USA) | ||
| 28.03. | ArriVent BioPharma reports FY results | 1 | Seeking Alpha | ||
| 28.03. | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports Full Year 2023 Financial Results | 104 | GlobeNewswire (Europe) | Company progresses the development of furmonertinib with a data readout planned for 2024Furmonertinib granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration Completed $201... ► Artikel lesen | |
| 06.03. | US Arrivent Biopharma, Ferguson, Target | 1 | Reuters | ||
| 20.02. | Citi starts ArriVent stock with buy rating citing promising lung cancer drug | 2 | Investing.com | ||
| 20.02. | ArriVent BioPharma stock gets Buy rating from Jefferies, highlights near term data | 1 | Investing.com | ||
| 02.02. | ArriVent Biopharma, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 30.01. | ArriVent Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.01. | ArriVent wows investors with promising China-developed lung cancer treatment | 1 | Bamboo Works | ||
| 26.01. | ArriVent's Nasdaq Debut Nabs $175M as Signs Indicate an Opening IPO Window | 1 | MedCity News | ||
| 26.01. | ArriVent takes in $175M from second biotech IPO of the year | 1 | FierceBiotech | ||
| 26.01. | Cancer biotech ArriVent BioPharma prices upsized IPO at $18 midpoint | 1 | Renaissance Capital | ||
| 26.01. | Then there were two: ArriVent set to list after $175m IPO | 2 | pharmaphorum | ||
| 26.01. | Arrivent Biopharma, Inc.: ArriVent Announces Pricing of Upsized Initial Public Offering | 432 | GlobeNewswire (Europe) | NEWTOWN SQUARE, Pa., Jan. 25, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. ("ArriVent") (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative... ► Artikel lesen | |
| 23.01. | ArriVent BioPharma upsizes proposed IPO to $150M from $100M | 2 | Seeking Alpha | ||
| 22.01. | Arrivent anticipates $135M IPO as biotechs continue to eye public market | 1 | FierceBiotech | ||
| 22.01. | Cancer biotech ArriVent BioPharma sets terms for $150 million IPO | 1 | Renaissance Capital | ||
| 22.01. | ArriVent BioPharma Announces 8.33M Share IPO at $17-$19/sh | 1 | Investing.com | ||
| 22.01. | ArriVent Biopharma, Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings |
Seite:
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 9,235 | +0,82 % | Aixtron, Auto1 Group, Evotec, MTU Aero Engines, Northern Data, SMA Solar und Co. - Aktien-Positionen der Shortseller | Wer Aktien leer verkauft, das sogenannte Shortselling, muss Transparenzpflichten erfüllen. Wir werfen einen Blick auf aktuelle Shortseller-Meldungen. Geregelt sind diese in der EU-Leerverkaufsverordnung... ► Artikel lesen | |
| QIAGEN | 38,760 | +2,16 % | Biotech Report: Sektor fester - Evotec und Qiagen können zulegen | (shareribs.com) Frankfurt / New York 22.04.2024 - Biotech-Aktien verzeichneten zum Wochenauftakt im deutschen Handel Kursgewinne. Gesucht waren unter anderem Evotec und Qiagen. Auch an der Wall Street... ► Artikel lesen | |
| CULLINAN THERAPEUTICS | 25,300 | +31,43 % | PEGY, CGEM and IFBD among mid-day movers | ||
| RECURSION PHARMACEUTICALS | 8,120 | +3,57 % | Recursion Pharmaceuticals' Options Frenzy: What You Need to Know | ||
| CABALETTA BIO | 11,010 | -9,61 % | Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - First patient dosed with CABA-201 in the RESET (REstoring SElf-Tolerance) clinical trial program - - Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 45,530 | +3,01 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | ||
| IMMUNOVANT | 27,170 | -2,09 % | Should You Hold Immunovant (IMVT)? | ||
| KEROS THERAPEUTICS | 57,86 | +6,77 % | Prozessmanagement in der Gemeinschaftsverpflegung / Keros Consult optimiert Warenwirtschaft für Eichhof-Stiftung Lauterbach | Düsseldorf (ots) - Ab sofort unterstützt Keros Consult, eine hundertprozentige Tochtergesellschaft der Klüh-Gruppe, die Eichhof-Stiftung Lauterbach bei der Optimierung ihrer Bestell- und Produktionsprozesse... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 24,360 | +2,22 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, April 22, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide... ► Artikel lesen | |
| DYNE THERAPEUTICS | 24,730 | +4,37 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer | WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for... ► Artikel lesen | |
| ARCELLX | 51,92 | +1,05 % | Should You Be Bullish on Arcellx (ACLX)? | ||
| DAY ONE BIOPHARMACEUTICALS | 14,920 | +12,94 % | Day One Biopharmaceuticals, Inc.: Day One's OJEMDA (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor | First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation RAPNO LGG overall response rate... ► Artikel lesen | |
| BIONTECH | 82,40 | +2,11 % | BioNTech Aktie: Hoffnung und Spekulation | Die BioNTech-Aktie verzeichnete zuletzt einen leichten Kursrückgang von 0,18% in einer Woche, mit einem aktuellen Wert von 81,45 Euro. Dieser Rückgang ist Teil eines erkennbaren Abwärtstrends, trotz... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 33,370 | +0,06 % | Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) | ||
| NUVALENT | 66,86 | +1,20 % | Nuvalent, Inc.: Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 | Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile
Zidesamtinib shown to... ► Artikel lesen |
Das Unternehmen ARRIVENT BIOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 15,440 Euro und damit -0,64 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
